5 citations
,
April 2023 in “Life” CCCA affects adolescents too, with genetic and environmental links, requiring careful diagnosis.
November 2024 in “Actas Dermo-Sifiliográficas” N-acetylcysteine and memantine are recommended as safe and effective treatments for trichotillomania.
15 citations
,
June 2019 in “Journal of Neuroendocrinology” Isoallopregnanolone may be a safe and effective treatment for reducing tics in a mouse model of Tourette syndrome.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
75 citations
,
March 2009 in “Journal of The American Academy of Dermatology” CCCA is a hair loss type affecting African women, possibly caused by grooming and chemicals, with various treatments and needing more research.
May 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Effective treatments for trichotillomania include cognitive-behavioral therapy, certain medications, and alternative support tools.
32 citations
,
November 2011 in “International Journal of Dermatology” Diagnose and manage CCCA with thorough history, exams, and labs; treat with anti-inflammatory agents, stress reduction, and stopping harmful hair practices.
May 2025 in “International Journal of Women’s Dermatology” CCCA mainly affects Black women and is linked to high-tension hairstyles, heating tools, chemical relaxants, and genetics.
September 2025 in “Cureus” There is no standard treatment for CCCA, and practices vary widely.
1 citations
,
September 2025 in “Pediatric Dermatology” Behavioral interventions, especially habit reversal training, are most effective for treating trichotillomania in children.
8 citations
,
October 2020 in “Clinical Psychopharmacology and Neuroscience” rTMS may help treat trichotillomania in some patients.
April 2026 in “Future Medicinal Chemistry” Proteolysis-Targeting Chimeras (PROTACs) have significantly transformed drug discovery by utilizing a unique catalytic degradation mechanism that targets and degrades specific proteins. This technology has progressed from a laboratory concept to achieving clinical breakthroughs, demonstrating its potential in treating various diseases. PROTACs offer advantages over traditional inhibitors by providing sustained protein degradation, which can lead to more effective and durable therapeutic outcomes. The development of PROTACs has opened new avenues for targeting previously "undruggable" proteins, marking a pivotal advancement in the field of medicinal chemistry and pharmacology.
January 2009 in “Epsilon: Revista de la Sociedad Andaluza de Educación Matemática "Thales"” A CCS patient with severe complications was successfully treated using combined therapies.
July 2017 in “OPAL (Open@LaTrobe) (La Trobe University)” High-throughput LC-MS screening is effective for finding new autotaxin inhibitors for asthma treatment.
September 2024 in “Journal of the American Academy of Dermatology” The compounded topical solution is safe, stable, and effective for personalized alopecia treatment.
2 citations
,
December 2020 in “American Journal of Dermatological Research and Reviews” The combination therapy was effective and well-tolerated, especially in young patients.
April 2023 in “Journal of Investigative Dermatology” Cyclosporin A, a drug, reduces TGF-β2 expression in skin cells, potentially causing excessive hair growth through a process involving the calcineurin/NFAT pathway.
3 citations
,
April 2022 in “Cutis” CCCA is a common, scarring hair loss in Black women that needs early detection.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.
21 citations
,
February 1988 in “Toxicology” High doses of TCB cause severe health issues in marmoset monkeys.
April 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Targeting cholesterol, fatty acids, fibrosis, and mast cells may help treat CCCA.
January 2025 in “Biomedical Reports” Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.
Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.
7 citations
,
April 2013 in “Clinical and Experimental Dermatology” Tianeptine, an antidepressant, may prevent stress-induced hair loss in mice.
5 citations
,
July 2019 in “Photodiagnosis and photodynamic therapy” Using tacalcitol ointment with photodynamic therapy may effectively treat follicular mucinosis with scalp hair loss.
The document plans to assess if Xiao-Chai-Hu-Tang is effective for chronic fatigue syndrome but has no results yet.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
4 citations
,
January 2001 in “Archives of Biochemistry and Biophysics” Activated ras can protect kidney cells from a certain substance that causes cell death.
88 citations
,
August 2019 in “Nature communications” Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.